Provided by Tiger Trade Technology Pte. Ltd.

Tarsus Pharmaceuticals, Inc.

66.25
-0.9500-1.41%
Post-market: 66.250.00000.00%16:34 EDT
Volume:352.46K
Turnover:23.59M
Market Cap:2.81B
PE:-41.67
High:68.87
Open:67.01
Low:66.09
Close:67.20
52wk High:85.25
52wk Low:38.51
Shares:42.45M
Float Shares:30.35M
Volume Ratio:0.62
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5900
EPS(LYR):-1.5900
ROE:-23.39%
ROA:-9.45%
PB:8.19
PE(LYR):-41.67

Loading ...

Stock Track | Tarsus Pharmaceuticals Soars 10.64% Intraday on Positive Analyst Ratings and Price Target Increases

Stock Track
·
Feb 24

Tarsus Pharmaceuticals price target raised to $90 from $88 at BofA

TIPRANKS
·
Feb 24

Stock Track | Tarsus Pharmaceuticals Soars 6.44% Pre-Market on Positive Analyst Outlook and Growth Prospects

Stock Track
·
Feb 24

Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline

TIPRANKS
·
Feb 24

Stock Track | Tarsus Pharmaceuticals Soars 6.15% After-Hours on Strong Q4 Revenue Beat and XDEMVY Sales Growth

Stock Track
·
Feb 24

Earnings Flash (TARS) Tarsus Pharmaceuticals Posts Q4 Loss $0.20, vs. Loss of $0.60 a Year Ago

MT Newswires Live
·
Feb 24

Stock Track | Tarsus Pharmaceuticals Soars 5.61% on Strong XDEMVY Sales Growth and Revenue Beat

Stock Track
·
Feb 24

Tarsus Pharmaceuticals Q4 EPS $(0.20) Misses $(0.11) Estimate, Sales $151.668M Beat $144.565M Estimate

Benzinga
·
Feb 24

BRIEF-Tarsus Pharmaceuticals Q4 EPS USD -0.2

Reuters
·
Feb 24

Tarsus posts FY 2025 XDEMVY net product sales of USD 451.4 million, up more than 150% YoY

Reuters
·
Feb 24

Tarsus Pharmaceuticals Inc - Phase 2 Study of Tp-05 for Lyme Disease in Q2 2026

THOMSON REUTERS
·
Feb 24

Tarsus Pharmaceuticals Inc - Xdemvy Expected Peak Sales Potential Over $2 Bln

THOMSON REUTERS
·
Feb 24

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

GlobeNewswire
·
Feb 24

Analysts’ Top Healthcare Picks: Telix Pharmaceuticals (TLPPF), Tarsus Pharmaceuticals (TARS)

TIPRANKS
·
Feb 22

Tarsus Pharmaceuticals Files Initial Beneficial Ownership Statement for Director David E.I. Pyott

Reuters
·
Feb 21

Tarsus Pharmaceuticals Adds Industry Veteran to Board

TIPRANKS
·
Feb 18

Tarsus Pharmaceuticals appoints Pyott to Board of Directors

TIPRANKS
·
Feb 18

Tarsus Pharmaceuticals Names Former Allergan CEO David Pyott to Board

Reuters
·
Feb 18

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to Its Board of Directors

THOMSON REUTERS
·
Feb 18

Tarsus Pharmaceuticals Inc. to report fourth quarter and full year 2025 financial results

Reuters
·
Feb 18